MVA-BN-brachyury-TRICOM vaccine
- Generic Name
- MVA-BN-brachyury-TRICOM vaccine
- Drug Type
- Biotech
- Unique Ingredient Identifier
- GD1ZWN2I2Y
Overview
MVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3. These immune-enhancing co-stimulatory molecules exert immunostimulatory and antineoplastic actions. MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)‐Brachyury booster vaccine.
Background
MVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3. These immune-enhancing co-stimulatory molecules exert immunostimulatory and antineoplastic actions. MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)‐Brachyury booster vaccine.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.